U.S. Pharmaceuticals Spend $8 Billion Annually in R&D Conducted Overseas – New Clintelligence(R) Alignment Module Advances Global Management
KENILWORTH, N.J. -- 3C Company, Inc., a leading provider of Business Performance Optimization (BPO) solutions to the Life Sciences Industry, announces today the release of a new module to its highly successful Clintelligence(R) Business Intelligence Solution.
News from the Battlefield of Metastatic Cancer: Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of...

Epeius Biotechnologies Gains FDA Approval for Two New Clinical Trials for Breast Cancer and Sarcoma
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation announced today the expansion of ongoing clinical trials using Rexin-G(TM) in the United States to include breast cancer and all types of sarcomas that have failed standard chemotherapy. Following on the heels of their landmark clinical trials in the United States and abroad, the US FDA granted Orphan Drug Status for Rexin-G.
Epeius Biotechnologies to Present the Advent of Tumor Targeting Technology at Biotech Conferences

Local Pharmacy is First in New Jersey to Earn Top Quality & Safety Endorsement
WASHINGTON, D.C. -- Belvidere Pharmacy is the first pharmacy in the state of New Jersey to earn the Pharmacy Compounding Accreditation Board's Seal of Accreditation - a new system of standards created by some of the leading organizations in pharmacy. The accreditation demonstrates that Belvidere Pharmacy meets the highest quality and safety standards in its profession.
Pharmaceutical Giants Take Aim at Tightening Productivity in Research and Development Using State-of-the Art Business Intelligence Tools
KENILWORTH, N.J. -- 3C Company, Inc. (www.3cpharma.com), a leading provider of Business Performance Optimization (BPO) solutions to the Life Sciences Industry, announced today that it has aligned with yet another Global Pharmaceutical Firm to implement Clintelligence - 3C Company's Business Intelligence Solution for strategic and tactical oversight of their Research and Development portfolio.
Libutol™ All Natural 'Feel Good' Pill Strikes a Chord with Millions of Women

Campbell Belman Releases Comprehensive Report for Pharmaceutical Marketers

Stauber Names Jim Freeman as Director of Sales and Marketing
FULLERTON, Calif. -- Stauber Performance Ingredients, Inc., announced today the appointment of Jim Freeman to the position of Director of Sales and Marketing. The position reports to John Milazzo, President of Stauber, and became effective on August 30, 2006.